Tvardi Therapeutics (TVRD) Accumulated Depreciation (2013 - 2023)

Tvardi Therapeutics has reported Accumulated Depreciation for 11 years, with the latest figure at $1.7 million in Q4 2023.

• Quarterly Accumulated Depreciation rose 18.31% year-over-year to $1.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.7 million (up 18.31% YoY) and the FY2023 annual result came in at $1.7 million, up 18.31% from the prior year.
• Accumulated Depreciation advanced to $1.7 million in Q4 2023 per TVRD's latest filing, from $1.4 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $1.7 million in Q4 2023 and troughed at $1.2 million in Q4 2021.
• A 5-year average of $1.4 million and a median of $1.4 million in 2022 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2021 and 2022: Accumulated Depreciation slipped 24.66% in 2021, then increased 21.36% in 2022.
• Over 5 years, Accumulated Depreciation stood at $1.3 million in 2019, then gained by 15.69% to $1.5 million in 2020, then declined by 24.66% to $1.2 million in 2021, then rose by 21.36% to $1.4 million in 2022, then advanced by 18.31% to $1.7 million in 2023.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $1.7 million, $1.4 million, and $1.2 million for Q4 2023, Q4 2022, and Q4 2021 respectively.